The results from ValiRx PLC’s (LON:VAL) mid-stage study of its VAL401 anti-cancer compound have been accepted for inclusion on ClinicalTrials.gov, a publicly accessible database.
The phase II trial, carried out over summer, showed that palliative stage lung cancer patients could expect to see improvements in quality of life as well as improved survival prospects.
READ: ValiRx in detailed discussions to take VAL401 into phase III
The chief executive of ValiSeek – the joint venture company which has developed VAL401 – Suzy Dilly, said: “The acceptance of the results into the independent external database satisfies the requirement to make publicly available all data from clinical trials, providing a statement of numerical listing of data.
“Although, along with the submission of the Clinical Study Report to the Ministry of Health in Tbilisi, this concludes our formal obligations on trial reporting, we are also in the process of publication through peer-reviewed industry journals, which will provide interpretation of these listed results.”
ValiRx, which plans to kick off a phase III trial in 2019, said the results from the mid-stage will be published onto the site shortly.
Shares soared 12.2% to 2.0p in early afternoon trading.